Edwards Lifesciences (EW) PT Raised to $130 at Stifel; Reiterates Buy

Stifel raised its price target on Edwards Lifesciences (NYSE: EW) to $130.00 (from $118.00) while maintaining a Buy rating. For 3Q17, the company anticipates revenue between $810M-$850M with EPS at $0.80-$0.90 (mid-point: $0.85).

For 2017, Edwards now expects full-year revenue at the “higher end” of the $3.2 billion to $3.4 billion range. At current rates, FX is now anticipated to represent a $20M full-year drag vs. the prior $50M expectation. On EPS, management now anticipates $3.65-$3.85 (mid-point: $3.75) vs. the prior $3.43-$3.55 (mid-point: $3.49) range.

You May Also Be Interested In

• Natera (NTRA) PT Raised to $270 at BTIG
• Norwegian Cruise (NCLH) PT Raised to $24 at TD Cowen
• United Airlines (UAL) PT Raised to $153 at UBS Ahead of Q2 Results